Live Breaking News & Updates on Michiels Van

Stay updated with breaking news from Michiels van. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium. ....

United States , Riccardo Lencioni , Michiels Van , Drug Administration , American Society , Clinical Oncology , Gastrointestinal Cancers Symposium , Genitourinary Cancers , Gastrointestinal Cancers , Der Heijden , Neal Shore , Gastric Cancer , Prostate Cancer , Kidney Cancer , Bladder Cancer , Asco Gi24 , Asco Gu24 ,

Survival Benefits with Keytruda and Padcev in Advanced Urothelial Cancer

Patients with previously untreated locally advanced or metastatic urothelial carcinoma experienced favorable progression-free survival, overall survival and objective response rates when treated with Padcev and Keytruda versus chemotherapy. ....

United States , Padcev Keytruda , Michiels Van , Michiel Van Der Heijden Research Group , Netherlands Cancer Institute , Drug Administration , Cancers Symposium , Der Heijden , Michiel Van , Heijden Research Group , North America , Bladder Cancer , Genitourinary Cancers Symposium ,

Enfortumab Vedotin Plus Pembrolizumab Maintains Survival Advantage Across Advanced Urothelial Cancer Subgroups

Enfortumab vedotin plus pembrolizumab showed consistent overall survival and progression-free survival benefit in all patients enrolled in EV-302. ....

Perez Valderrama , Michiels Van , Bristol Myers Squibb , Astellas Pharma , Gilead Sciences , Cancers Symposium , Der Heijden , Enfortumab Vedotin , Asco Gu , Genitourinary Cancers Symposium , Ev 302 , Keynote A39 Trial , Michiels Van Der Heijden , Netherlands Cancer Institute , Subgroup Analysis , Urothelial Carcinoma ,

Frontline Nivolumab Plus Chemotherapy Boosts OS and PFS in Metastatic Urothelial Carcinoma

Concurrent frontline nivolumab and gemcitabine-cisplatin followed by nivolumab maintenance therapy elicited OS and PFS benefits vs gemcitabine-cisplatin alone in patients with previously untreated, metastatic or unresectable urothelial carcinoma. ....

Noord Holland , Michiels Van , Netherlands Cancer Institute , Concurrent Frontline Nivolumab And Gemcitabine Cisplatin , Urothelial Carcinoma , Checkmate 901 Study , Michiels Van Der Heijden ,

Opdivo Plus Chemo Betters Survival in Urothelial Carcinoma

Adding Opdivo to a standard-of-care chemotherapy regimen in patients with unresectable or metastatic urothelial carcinoma improved progression-free and overall survival. ....

Noord Holland , Michiels Van , Netherlands Cancer Institute , Adding Opdivo , Esmo 2023 ,